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Abstract
Background—Brain metastases are one of the most malignant complications of lung cancer and 
constitute a significant cause of cancer related morbidity and mortality worldwide. Recent years of 
investigation suggested a role of LKB1 in NSCLC development and progression, in synergy with 
KRAS alteration. In this study, we systematically analyzed how LKB1 and KRAS alteration, 
measured by mutation, gene expression (GE) and copy number (CN), are associated with brain 
metastasis in NSCLC.
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Materials and Methods—Patients treated at University of North Carolina Hospital from 1990 
to 2009 with NSCLC provided frozen, surgically extracted tumors for analysis. GE was measured 
using Agilent 44,000 custom-designed arrays, CN was assessed by Affymetrix GeneChip Human 
Mapping 250K Sty Array or the Genome-Wide Human SNP Array 6.0 and gene mutation was 
detected using ABI sequencing. Integrated analysis was conducted to assess the relationship 
between these genetic markers and brain metastasis. A model was proposed for brain metastasis 
prediction using these genetic measurements.
Results—17 of the 174 patients developed brain metastasis. LKB1 wild type tumors had 
significantly higher LKB1 CN (p < 0.001) and GE (p = 0.002) than the LKB1 mutant group. KRAS 
wild type tumors had significantly lower KRAS GE (p < 0.001) and lower CN, although the latter 
failed to be significant (p = 0.295). Lower LKB1 CN (p = 0.039) and KRAS mutation (p = 0.007) 
were significantly associated with more brain metastasis. The predictive model based on nodal (N) 
stage, patient age, LKB1 CN and KRAS mutation had a good prediction accuracy, with area under 
the ROC curve of 0.832 (p < 0.001).
Conclusion—LKB1 CN in combination with KRAS mutation predicted brain metastasis in 
NSCLC.
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Introduction
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in the 
United States with brain metastasis as one of the most dreaded complications [1]. 
Historically, the prognosis of NSCLC with brain metastasis has been poor, with a median 
overall survival of 4.5 months for patients treated with standard whole brain radiation 
therapy (WBRT) and 4–11 weeks in untreated patients [2, 3]. The prevalence of brain 
metastasis in NSCLC is reported to be increasing, possibly due to improved diagnosis in 
brain imaging and prolonged survival with new systemic treatment options [4]. Therefore, 
identification of biomarkers that have critical roles in cell growth, metabolism, and tumor 
recurrence would provide valuable information in disease prognosis and better treatment 
choices.
In the past few years, several lines of evidence implicate the importance of liver kinase B1 
(LKB1, aka, serine-threonine kinase or STK11) as a tumor suppressor gene in lung cancer 
development and progression in both human and model organisms [5, 6]. LKB1 was first 
identified in 1997 as the causative mutation in the autosomal-dominant inherited Peutz–
Jeghers Syndrome (PJS) [7]. LKB1 loss is one of the most frequent genetic alterations in 
NSCLC [8], the inactivation of which has also been proposed to be associated with tumor 
metastasis in lung cancer and other tumor types [5, 6, 9]. Specifically, LKB1 mutation or 
loss of heterozygosity (LOH) of 19p13.2 which harbors the LKB1 gene was observed in a 
much higher proportion in brain metastases of lung cancer patients than in the primary 
tumors [5, 10].
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As with many tumor suppressor genes, identifying patients with LKB1 inactivation remains 
a challenge, with potential mechanisms including homozygous deletion, point mutations and 
epigenetic silencing [5, 6]. The discrepancy between the high frequency of LOH (often over 
50%) of 19p13.3 [11] and the reported rate of LKB1 mutation [5, 8] suggests that many 
“second hits” to the gene may go undetected by current sequencing techniques or that 
epigenetic silencing or other inactivating events may be more prevalent than previously 
recognized. In any case, for the purposes of clinical assessment, investigators are challenged 
to assess the gene through multiple mechanisms to gain confidence in characterizing the 
gene as intact or altered. In addition, multiple investigators have now reported coordination 
between losses of LKB1 and the oncogene, KRAS, particularly in smokers suggesting that 
coordinated assessment may be clinically relevant.
In this study, we seek to identify how LKB1 alteration, assessed by gene mutation, gene 
expression (GE) and copy number (CN) change, can predict brain metastasis in a group of 
NSCLC patients in conjunction with KRAS aberration, which has been shown to have a 
synergistic effect with LKB1 inactivation in lung cancer development and metastasis [6].
Material and Method
Tumor collection and clinical data abstraction
Frozen tumors were collected from patients who received curative surgery at the University 
of North Carolina (UNC) hospital with NSCLC diagnosis from December 1990 to 
September 2009. Tissues were flash-frozen and stored at −80 °C until time of analysis. 
Tumor histology includes adenocarcinoma [12], adenosquamous carcinoma, 
bronchioloalveolar carcinoma, large cell carcinoma and squamous cell carcinoma [13]. 
Patient outcomes were assessed by retrospective chart review for vital status and tumor 
recurrence, including brain metastasis through the end of the study, January 2011. For any 
patients whose follow-up was not at the UNC, records were requested from outside treating 
facilities. Assessment of brain metastasis was made by review of all radiology reports of 
brain imaging or pathology in cases of brain tissue resection. Patients were only assessed as 
having a metastasis if a radiology report concluded definitively that a brain metastasis was 
present in the summary conclusion of the official report. In cases where no brain imaging 
was performed, a patient was assessed as negative for brain metastasis. In cases where a 
patient had both imaging and tissue confirmation of brain metastasis, the time to recurrence 
was estimated based of the first positive report. The study was approved by Institutional 
Review Board (IRB) under protocols 90-0573 and 07-0120.
Gene expression microarray
GE was measured by Agilent 44 K microarrays (human tumor). Total RNA from tumor 
tissues was isolated using the RNeasy kit following the manufacturer’s protocols (Qiagen, 
Valencia, CA, USA). Total RNA-1ug was converted to labeled cRNA with nucleotides 
coupled to a fluorescent dye (Cy3) using the Quick Amp Kit (Agilent Technologies, Palo 
Alto, CA). Universal RNA from Invitrogen was labeled with Cy5 as a reference. Samples 
were purified using an RNeasy kit (Qiagen) and quantified for dye integration using a 
Nanodrop-8000 (Thermo Scientific). Following quantification, samples were hybridized 
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overnight in a rotating hybridization oven and washed/scanned using an Agilent scanner. 
Microarrays were processed by normexp background correction and loess normalization [13, 
14].
LKB1 and KRAS mutations
Genomic DNA was extracted from tumor tissues using Qiagen QiaAmp DNA kit and sent to 
Polymorphic DNA Technologies, Inc. (Almeda CA) for direct exon sequencing on ABI 
3730XL DNA sequencers to detect LKB1 and KRAS mutations. Regions of LKB1 and KRAS 
sequencing were described elsewhere [12], with all nine exons of LKB1 and exon 2 of 
KRAS, which harbors more than 95% of KRAS mutation [15] sequenced. Non-synonymous 
or splice site differences compared to reference sequence were considered as mutations [16].
LKB1 and KRAS CN assessment
CN microarray of tumor DNA was performed using the Affymetrix GeneChip Human 
Mapping 250K Sty Array or the Genome-Wide Human SNP Array 6.0 (Affymetrix, Inc., 
Santa Clara, CA) according to the manufacturer’s instructions. CN for each marker was 
calculated using CRMA_v2 [17], which performs log2 transformation on preprocessed 
signal intensity. CN for each marker was taken to be log2(tumor sample/normal estimate), 
where the normal estimate was calculated using the mean intensity from all normal 
specimens. CN for LKB1 and KRAS in each sample was taken as the mean values of 
estimated copy numbers across all markers that are within the 100 kb region upstream or 
downstream of the genes.
Statistical analysis
All statistical analysis was performed using R 2.10.1 software (http://cran.r-project.org) 
unless otherwise stated. Patients follow up time was calculated using “reverse” Kaplan-
Meier analysis in which the outcomes ‘dead’ and ‘censored’ are exchanged [18]. This 
method distinguishes the observation time between patients who were lost to follow up and 
patients who died during the study. The unobservable follow up time for a deceased patient 
is considered as the potential follow up time that would have been obtained had that patient 
not died [19]. Pairwise association between patients’ baseline characteristics, including 
gender, race, stage, tumor histology and smoking status, and genetic biomarkers, including 
LKB1 and KRAS mutation, GE and CN, were tested using Fisher’s exact test for categorical 
variables and two sample t-test for continuous variables. Logistic regression was used to test 
the association between each of the variables and brain metastasis. Variables showed 
significant association with brain metastasis at α = 0.05 level in univariate analysis were 
included in multivariate analysis. For all the analyses, a complete case approach was used to 
handle missing data. All statistical tests were two sided tests and all reported confidence 
intervals were constructed at a two sided 95% confidence level.
Result
Patient characteristics with respect to genetic biomarkers
174 of the patients provided sufficient tissue for at least one measurement of LKB1 
alteration and were included in subsequent analysis, in which 172 had GE measurement, 162 
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had CN and 172 had mutation data. Diagnosis age ranges from 39 to 90 with a median of 66 
years; approximately half of these patients (88) are males and most of them (161) had 
smoking history. The majority of these patients (153) were diagnosed when the tumor was 
still small (T1 or T2). Half of the patients (87) had adenocarcinoma, and most of the others 
had squamous cell carcinoma (57) or adenosquamous carcinoma (10). The median follow up 
time calculated from the reverse KM method was 91 months. Only 11 patients were lost to 
follow up before 60 months, with a median follow up time of 51 months. The median 
survival time of all 174 patients was 42 months (95% CI: 33–58 months). Seventeen of these 
patients had brain recurrence with a median survival time after brain metastasis of 6.8 
months (95% CI: 2.67 –49.9 months). 3 of 17 patients developed brain metastases within 6 
months of cancer diagnosis. An additional 13 patients developed recurrence within 5 years 
at a median and mean of 12 and 17 months respectively. One patient developed an unusual 
late brain only recurrence at 86 months which was nonetheless clinically determined to be 
originating from the remote lung cancer. Brain only recurrence was seen in 13 of 17 patients 
as the first sight of recurrence at a median of 8 months after initial diagnosis. The remaining 
4 patients developed brain metastasis at later stages of the disease or in conjunction with 
multiple sites of disease at a median of 19 months after initial diagnosis.
Table 1 summarized how patient characteristics associated with genetic biomarkers LKB1 
and KRAS. Overall, 21 samples (12.2%) sequenced for LKB1 had non-synonymous or splice 
site mutation and 22 (12.9%) had canonical mutations in KRAS. Consistent with previous 
research [8, 20], LKB1 mutations were more common in adenocarcinoma (13/85) than in 
non-adenocarcinoma (8/87), although the difference failed to be significant (p = 0.25). 
Similarly, KRAS mutations were more frequent in adenocarcinoma (20/85) than other tumor 
histology (2/86, p < 0.001). Accordingly, adenocarcinomas had significantly lower LKB1 
expression (p < 0.001), lower LKB1 CN (p = 0.003) and higher KRAS expression (p = 0.035) 
compared to the non-adenocarcinoma group. Also consistent with previous reports, smoking 
was associated with LKB1 and KRAS mutation [20]: all samples that were mutant for LKB1 
were smokers and only one KRAS mutant was a non-smoker, although the association was 
not significant. Both LKB1 and KRAS mutation were associated with earlier T stage. Gender 
and race were not associated with LKB1 or KRAS measurement.
Associations between genetic markers
Alterations of LKB1 and KRAS were further interrogated as a function of GE and CN 
(Figure 1–2). LKB1 mutation was significantly associated with lower GE (Figure 1A, p = 
0.002) and lower CN (Figure 1C, p < 0.001). On the contrary, KRAS mutation was 
associated with higher expression (Figure 2A, p < 0.001). There is no significant association 
between KRAS mutation and KRAS CN (Figure 2C). CN and GE are positively correlated in 
both LKB1 and KRAS (Figure 1B, 2B, p < 0.001).
Univariate association of patient characteristics and genetic markers with brain recurrence
Seventeen of the patients had brain metastasis during the follow up. Patients’ characteristics 
with respect to brain metastasis were summarized in Table 2. Neither gender nor race was 
associated with brain recurrence. All but one patient with brain metastasis were current/
former smokers. Of all patients with brain recurrence, only one had late T (T3 or T4) stage 
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at diagnosis. However, the association failed to be significant because of the small number 
of brain recurrence. Clinical N stage was significantly associated with brain metastasis (OR 
= 4.87, CI: 1.74–14.9). Brain recurrence in adenocarcinoma (11/87) was more frequent than 
in non-adenocarcinoma (6/87), although the association failed to be significant (p = 0.21). 
Of the genetic markers, KRAS mutation and LKB1 CN were significantly associated with 
brain metastasis (p = 0.007 and 0.039 respectively). Higher LKB1 expression and LKB1 wild 
type were also associated with fewer brain metastases, although the result did not achieve 
statistical significance.
Multivariate association of patient characteristics and genetic markers with brain 
recurrence
Variables that were significantly associated with brain recurrence in univariate models were 
considered for inclusion in the multivariate model (Table 3). 154 patients had complete data 
for all the gene measurements and were included in the multivariate models. LKB1 CN and 
KRAS mutation were significantly associated with brain recurrence after adjusting for patient 
age and nodal status. Patients with higher LKB1 CN or wild type KRAS had lower risk of 
developing brain recurrence. The odds of brain metastasis in mutant KRAS patients were 
estimated to be 5.52 (CI: 1.31–22.6) times higher than the odds of brain recurrence in 
patients with wild type KRAS, after adjusting for age, LKB1 CN and N stage. The odds ratio 
of brain metastasis was ~20 times higher in patients with one decrease in LKB1 CN values, 
after controlling for age, KRAS mutation and N stage. Considering the fact that variables 
may confound or interact with each other in multivariate model, another multivariate model 
which includes all variables that had p value < 0.20 was fitted and the result was similar to 
the result in table 3 (not shown).
Model predictions of brain metastasis
A linear predictor based on LKB1 CN, KRAS mutation, N stage and diagnosis age was 
constructed from the previously described multivariate model by using the model estimates. 
ROC curve was used to evaluate the prediction of this multivariate model (Figure 3). Area 
under the curve (AUC) was estimated to be 0.832 and significantly different from 0.5 (p < 
0.001, CI: 76.6%–93.5%). The ROC curve suggests the test performance over a range of 
potential cut points on this linear predictor. The optimal cut points cannot be clearly defined 
because this will depend on user preference for defining false positives and false negatives. 
For example, with a false positive rate of approximately 30%, the model successfully 
captured 80% of the true brain metastasis patients.
Discussion
The poor outcomes of patients with lung cancer have been widely reported, including the 
frequent occurrence of brain metastases in patients who have otherwise controlled their 
disease through primary therapy. In small cell lung cancer progress has been made towards 
preventing brain metastases through prophylactic cranial radiation which has a proven 
survival benefit [21]. Attempts to extend this benefit to patients with NSCLC have similarly 
documented a small benefit in terms of prevention of brain metastasis but without impact on 
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survival [22, 23]. Such data suggest that biomarkers to enrich for patients at highest risk for 
brain metastasis may be necessary to make progress in NSCLC.
LKB1 is one of the most important tumor suppressor genes and is observed to be inactivated 
in approximately 30% of all NSCLCs [8]. LKB1 encodes a widely expressed serine/
threonine protein kinase whose primary action is through 5′-AMP-activated protein kinase 
(AMPK) to regulate metabolism and ensure efficient energy production in times of stress 
[24]. Decreased expression of AMPK pathway genes have also been shown to be related to 
metastasis in NSCLC [25]. AMPK controls cell proliferation through the mammalian target 
of rapamycin (mTOR) kinase, which regulates numerous downstream targets [26]. LKB1 
loss impairs downstream AMPK signaling, leading to unsuppressed cell proliferation. LKB1 
deficiency can be associated with increased expression of genes believed to control 
angiogenesis and metastatic potential [9].
LKB1 can be inactivated through a variety of mechanisms, including gene mutation, deletion 
and epigenetic events, like promoter methylation. Somatic mutations, mainly nonsense or 
frameshift mutation, can result in truncated and dysfunctional proteins [27]. As has been 
shown in this study as well as previous research [5, 28], somatic mutation can account for 
only a small fraction of tumors and cannot be the sole reason of LKB1 inactivation. 
Promoter methylation, resulting in reduced expression, was shown to account for a small 
percentage of depressed LKB1 expression as well [29]. Gene deletion is a frequent 
mechanism of LKB1 loss, which can be assessed by CN [30]. The fact that the LKB1 mutant 
group also had lower CN is consistent with the common two-hit model for tumorigenesis 
which requires an individual to be heterozygous for a mutant tumor suppressor gene to lose 
the normal allele in order for tumor development to occur, which is frequently achieved 
through deletion of the normal allele. Based on clear evidence in animal models that LKB1 
haploinsufficiency accelerates KRAS driven lung cancer in mice [6], even a single copy 
inactivation of LKB1 might be oncogenic. A striking result from murine melanocyte models 
showed that somatically LKB1 inactivation and KRAS activation can induce highly 
metastatic melanoma with 100% penetrance, suggesting that LKB1 inactivation can greatly 
facilitate recurrence, especially in the context of RAS activation [31].
Studies on effects of KRAS alteration on metastasis in NSCLC is less conclusive than of 
LKB1. A recent report [32] on a specific stage IV NSCLC patient population indicated that 
KRAS was not associated with increase brain metastases; however, the result cannot be 
extrapolated directly to the surgically treated NSCLC patient population such as in the 
current study where the goal is prediction of future brain metastasis. The current study 
assessed the effect of LKB1 and KRAS in the same model, and may clarify that brain 
metastasis is part of the adverse outcomes of the combined LKB1/KRAS abnormality. CN 
might be a good proxy for LKB1 mutation, supported by our result that the mutated group is 
associated with reduced CN. It is also possible that a combination of these events is at work 
in inducing cancers and tumor invasion. Finding the best measurement that can adequately 
predict brain metastasis and is relatively straightforward to estimate in the clinical setting is 
very helpful in patient management.
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The current study has limitations inherent to retrospective genomic analyses of clinical 
outcomes. The overall number of brain metastases was limited and the sample size was 
modest. It is therefore important to put the current study in the context of prior case reports 
of brain relapses in lung cancer. It is well established that the rate of brain metastasis in lung 
cancer is associated with both increasing tumor stage and adenocarcinoma histology. While 
autopsy series have reported incidence as high as 54% in lung adenocarcinoma, surgical 
case series of mixed histologic types have generally documented lower rates of brain 
recurrence in a stage specific manner. A large study by Figlin reported rates as low as 7% in 
a population of surgically treated patients of all histologic subtypes which is comparable to 
the rate of 9.7% seen in the current analysis [34]. As expected, both in the report by Figlin 
and in the current study, increasing tumor stage and adenocarcinoma subtype either trended 
towards or were significantly associated with brain recurrence. In both reports, relapse in the 
brain alone, without other systemic disease, was the most common pattern. We conclude 
that although the current study is small in size, the patterns seen are reflective of those seen 
in larger surgical case series.
From a statistical modeling standpoint, since the overall number of brain metastases was 
limited, validation techniques such as split sample cross validation were excluded. 
Therefore, the estimated odds ratio should be used as an indication of association direction, 
rather than being a concrete measurement of genetic effect. On the other hand, a significant 
p value with a modest sample size usually entails a potentially large effect size. The aim of 
this study is to find clinical relevant markers which can help with patient management, 
instead of evaluating the mechanism by which LKB1 is involved in NSCLC brain 
metastasis. On the other hand, the hypothesis of this study was driven by previous reports 
that KRAS and LKB1 predominant subtypes identified by unbiased expression profiling were 
associated with adverse events, including a preliminary report of increased brain metastasis 
[12] as well as profiling of metastatic lesions noted to have LOH for LKB1. Additionally, 
while SNP chips similar to those used in the current study are available for clinical use, in 
general their clinic use is the assessment of inherited chromosomal abnormalities rather than 
somatic alterations in tumors [35]. As such any conclusions must be validated through 
additional larger patient cohorts and using reagents appropriate for the assessment of 
somatic alterations in tumors.
In conclusion, we present a predictive model for the occurrence of brain metastases in lung 
cancer based on common coordinated alterations in NSCLC. If validated these findings 
could be the basis on which future therapies and diagnostics could be developed for the 
treatment of brain metastases in this disease.
Acknowledgments
Funding: This study was supported by the Thomas G. Labreque Foundation, through Joan’s Legacy Foundation 
and by a Clinical/Translational Award from the UNC Lineberger Comprehensive Cancer Center.
References
1. Laskin, JJSA.; Johnson, DH. Philadelphia, PA. Non-Small Cell Lung Cancer. Philadelphia, PA: 
2005. 
Zhao et al. Page 8













2. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R. 
Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology 
Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997; 37:745–751. [PubMed: 
9128946] 
3. Ampil F, Caldito G, Milligan S, Mills G, Nanda A. The elderly with synchronous non-small cell 
lung cancer and solitary brain metastasis: does palliative thoracic radiotherapy have a useful role? 
Lung Cancer. 2007; 57:60–65. [PubMed: 17368627] 
4. Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK. The biology of brain 
metastases-translation to new therapies. Nat Rev Clin Oncol. 2011; 8:344–356. [PubMed: 
21487419] 
5. Matsumoto S, Iwakawa R, Takahashi K, Kohno T, Nakanishi Y, Matsuno Y, Suzuki K, Nakamoto 
M, Shimizu E, Minna JD, Yokota J. Prevalence and specificity of LKB1 genetic alterations in lung 
cancers. Oncogene. 2007; 26:5911–5918. [PubMed: 17384680] 
6. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura 
T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy 
J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro 
GI, Janne PA, Johnson BE, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless 
NE, Wong KK. LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007; 
448:807–810. [PubMed: 17676035] 
7. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, 
Aminoff M, Hoglund P, Jarvinen H, Kristo P, Pelin K, Ridanpaa M, Salovaara R, Toro T, Bodmer 
W, Olschwang S, Olsen AS, Stratton MR, de la Chapelle A, Aaltonen LA. A serine/threonine 
kinase gene defective in Peutz-Jeghers syndrome. Nature. 1998; 391:184–187. [PubMed: 9428765] 
8. Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM, Westra WH, Herman 
JG, Sidransky D. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. 
Cancer Res. 2002; 62:3659–3662. [PubMed: 12097271] 
9. Zhuang ZG, Di GH, Shen ZZ, Ding J, Shao ZM. Enhanced expression of LKB1 in breast cancer 
cells attenuates angiogenesis, invasion, and metastatic potential. Mol Cancer Res. 2006; 4:843–849. 
[PubMed: 17114342] 
10. Tiainen M, Ylikorkala A, Makela TP. Growth suppression by Lkb1 is mediated by a G(1) cell 
cycle arrest. Proc Natl Acad Sci U S A. 1999; 96:9248–9251. [PubMed: 10430928] 
11. Sobottka SB, Haase M, Fitze G, Hahn M, Schackert HK, Schackert G. Frequent loss of 
heterozygosity at the 19p13. 3 locus without LKB1/STK11 mutations in human carcinoma 
metastases to the brain. J Neurooncol. 2000; 49:187–195. [PubMed: 11212897] 
12. Wilkerson MD, Yin X, Walter V, Zhao N, Cabanski CR, Hayward MC, Miller CR, Socinski MA, 
Parsons AM, Thorne LB, Haithcock BE, Veeramachaneni NK, Funkhouser WK, Randell SH, 
Bernard PS, Perou CM, Hayes DN. Differential pathogenesis of lung adenocarcinoma subtypes 
involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS 
One. 2012; 7:e36530. [PubMed: 22590557] 
13. Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR, Muldrew K, Miller CR, 
Randell SH, Socinski MA, Parsons AM, Funkhouser WK, Lee CB, Roberts PJ, Thorne L, Bernard 
PS, Perou CM, Hayes DN. Lung squamous cell carcinoma mRNA expression subtypes are 
reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res. 2010; 
16:4864–4875. [PubMed: 20643781] 
14. Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, Holloway A, Smyth GK. A comparison 
of background correction methods for two-colour microarrays. Bioinformatics. 2007; 23:2700–
2707. [PubMed: 17720982] 
15. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-ras mutations in non-small-cell lung 
carcinoma: a review. Clin Lung Cancer. 2006; 8:30–38. [PubMed: 16870043] 
16. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-
throughput sequencing data. Nucleic Acids Res. 2010; 38:e164. [PubMed: 20601685] 
17. Bengtsson H, Ray A, Spellman P, Speed TP. A single-sample method for normalizing and 
combining full-resolution copy numbers from multiple platforms, labs and analysis methods. 
Bioinformatics. 2009; 25:861–867. [PubMed: 19193730] 
Zhao et al. Page 9













18. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991; 9:191–192. [PubMed: 1985169] 
19. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin 
Trials. 1996; 17:343–346. [PubMed: 8889347] 
20. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, 
Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, 
Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, 
Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-
Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl 
C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery 
T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, 
Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, 
Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba, Ozenberger B, Good PJ, Chang AC, Beer 
DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, 
Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M, Wilson RK. 
Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455:1069–1075. 
[PubMed: 18948947] 
21. Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, Postmus P, Collette L, Musat 
E, Senan S. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 
2007; 357:664–672. [PubMed: 17699816] 
22. Stuschke M, Eberhardt W, Pottgen C, Stamatis G, Wilke H, Stuben G, Stoblen F, Wilhelm HH, 
Menker H, Teschler H, Muller RD, Budach V, Seeber S, Sack H. Prophylactic cranial irradiation 
in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up 
and investigations of late neuropsychologic effects. J Clin Oncol. 1999; 17:2700–2709. [PubMed: 
10561344] 
23. Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik 
M, Choy H. Phase III comparison of prophylactic cranial irradiation versus observation in patients 
with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology 
group study RTOG 0214. J Clin Oncol. 2010; 29:272–278. [PubMed: 21135270] 
24. William WN, Kim JS, Liu DD, Solis L, Behrens C, Lee JJ, Lippman SM, Kim ES, Hong WK, 
Wistuba, Lee HY. The impact of phosphorylated AMP-activated protein kinase expression on lung 
cancer survival. Ann Oncol. 2011; 23:78–85. [PubMed: 21430184] 
25. Nanjundan M, Byers LA, Carey MS, Siwak DR, Raso MG, Diao L, Wang J, Coombes KR, Roth 
JA, Mills GB, Wistuba, Minna JD, Heymach JV. Proteomic profiling identifies pathways 
dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion 
pathways with recurrence. J Thorac Oncol. 5:1894–1904. [PubMed: 21124077] 
26. Makowski L, Hayes DN. Role of LKB1 in lung cancer development. Br J Cancer. 2008; 99:683–
688. [PubMed: 18728656] 
27. Launonen V. Mutations in the human LKB1/STK11 gene. Hum Mutat. 2005; 26:291–297. 
[PubMed: 16110486] 
28. Bignell GR, Barfoot R, Seal S, Collins N, Warren W, Stratton MR. Low frequency of somatic 
mutations in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer. Cancer Res. 1998; 
58:1384–1386. [PubMed: 9537235] 
29. Esteller M, Avizienyte E, Corn PG, Lothe RA, Baylin SB, Aaltonen LA, Herman JG. Epigenetic 
inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome. Oncogene. 
2000; 19:164–168. [PubMed: 10644993] 
30. Gill RK, Yang SH, Meerzaman D, Mechanic LE, Bowman ED, Jeon HS, Roy Chowdhuri S, 
Shakoori A, Dracheva T, Hong KM, Fukuoka J, Zhang JH, Harris CC, Jen J. Frequent 
homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene. 2011; 
30:3784–3791. [PubMed: 21532627] 
31. Liu W, Monahan KB, Pfefferle AD, Shimamura T, Sorrentino J, Chan KT, Roadcap DW, Ollila 
DW, Thomas NE, Castrillon DH, Miller CR, Perou CM, Wong KK, Bear JE, Sharpless NE. 
LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in 
melanoma. Cancer Cell. 2012; 21:751–764. [PubMed: 22698401] 
32. Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, Bunn PA Jr, Baron AE, 
Franklin WA, Aisner DL, Varella-Garcia M, Camidge DR. Oncogene status predicts patterns of 
Zhao et al. Page 10













metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer. 118:4502–4511. [PubMed: 
22282022] 
33. Cox JD, Yesner RA. Adenocarcinoma of the lung: recent results from the Veterans Administration 
Lung Group. Am Rev Respir Dis. 1979; 120:1025–1029. [PubMed: 228572] 
34. Figlin RA, Piantadosi S, Feld R. Intracranial recurrence of carcinoma after complete surgical 
resection of stage I, II, and III non-small-cell lung cancer. N Engl J Med. 1988; 318:1300–1305. 
[PubMed: 2834646] 
35. Shaikh TH. Oligonucleotide arrays for high-resolution analysis of copy number alteration in 
mental retardation/multiple congenital anomalies. Genet Med. 2007; 9:617–625. [PubMed: 
17873650] 
Zhao et al. Page 11













• We analyzed how LKB1 and KRAS alteration, measured by mutation, gene 
expression and copy number (CN), are associated with brain metastasis in 
NSCLC.
• LKB1 CN and KRAS mutation were significantly associated with brain 
metastasis after adjusting for other variables.
• We constructed a predictive model based on LKB1 CN and KRAS mutation for 
brain metastasis in NSCLC with good prediction accuracy.
• If validated, the prediction model may serve as the basis on which further 
diagnosis and therapies for the treatment of brain metastasis in NSCLC.
Zhao et al. Page 12














Correlation between LKB1 gene expression and copy number measurement. Panel A: LKB1 
wild type group had significantly higher gene expression. Panel B: LKB1 GE and CN were 
positively correlated. Panel C: Wild type group had significantly higher CN. CN for each 
marker was calculated as log2 intensity ratio between tumor samples and normal samples 
using CRMA_v2 [17]. GE microarray was preprocessed by Loess normalization and GE 
values are unit-less values.
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Correlation between KRAS gene expression and copy number measurement.. Panel A: KRAS 
wild type samples had a significantly lower gene expression. Panel B: KRAS expression and 
copy number were positively correlated. Panel C: Wild type group had significantly lower 
copy number. CN for each marker was calculated as log2 intensity ratio between tumor 
samples and normal samples using CRMA_v2 [17]. GE microarray was preprocessed by 
Loess normalization and GE values are unit-less values.
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ROC curve for the multivariant predictive model. Predictors in this model include LKB1 
CN, KRAS mutation, patients’ age at diagnosis and nodal stage. P values were generated by 
testing the hypothesis that area under the cuver (AUC) is 0.5.
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Table 2
Patient characteristics and genetic marker by disease outcome
brain recurrence (Column %) no brain recurrence (Column %) Odds Ratio ϕ (95% CI) P values
# of patients 17 157
Age at Diagnosis(mean) 57.4 65.7
Gender
 Female 9(52.9) 77(49.0) 1.17 0.76
 Male 8(47.1) 80(51.0) (0.43–3.26)
Race
 Whiteζ 12(70.6) 129(82.1) 0.47 0.183
 Black 5(29.4) 25(15.9) (0.157–1.56)
Smoking status ζ
 Current/Former Smoker ζ 16(94.1) 145 (92.9) 1.214 0.857
 Never/Light Smoker 1(5.88) 11(7.05) (0.21–22.9)
Tumor histology ζ
 Adenocarcinoma 11(64.7) 76(48.4) 1.95 0.21
 Non-adenocarcinoma 6(35.3) 81(51.6) (0.707–5.91)
T stages ζ
 T3-T4 1(5.88) 18(11.6) 0.476 0.48
 T0-T1-T2 16(94.1) 137(88.4) (0.026–2.56)
N stages ζ
 N1 or above 11(64.7) 41(27.3) 4.87 0.003
 N0 6(35.3) 109(72.7) (1.74–14.9)
LKB1 mutation ζ
 Mutant 3(17.6) 18(11.6) 1.63 0.47
 Wild type 14(82.4) 137(88.4) (0.35–5.62)
LKB1 expression ζ 0.574 0.32
mean 0.447 0.570 (0.187–1.65)
LKB1 copy number ζ 0.103 0.039
(mean) −0.051 0.120 (0.01–0.81)
KRAS mutation ζ
 Mutant 6(35.3) 16(10.4) 4.71 0.007
 Wild type 11(64.7) 138(89.6) (1.46–14.2)
KRAS expression ζ 0.83 0.63
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brain recurrence (Column %) no brain recurrence (Column %) Odds Ratio ϕ (95% CI) P values
mean −0.127 −0.041 (0.388–1.69)
KRAS copy number ζ 0.552 0.67
mean 0.0506 0.0776 (0.024–5.52)
ζ
number doesn’t sum to total because of missing values
ϕ
For each variable, the reported value was the odds ratio of brain metastasis in patients with characteristics in the first row compared to the patients 
with characteristics in the second row. For example, for gender, the odds of having brain recurrence in females are 1.429 times the odds of brain 
metastasis in males. Odds ratios, confidence intervals and p values were generated by fitting logistic models using each of the variables with brain 
recurrence as response variable.
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Table 3
Multivariate association between genetic biomarkers and disease outcome
Odds Ratio 95% CI P values
Age at diagnosis 0.95 0.89–1.00 0.056
LKB1 copy number loss 19.04 1.59–307 0.026
KRAS mutation 5.52 1.31–22.6 0.016
N stage 4.46 1.26–17.5 0.023
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